434941-55-6

Usage

Uses

Used in Pharmaceutical Industry:
4-(4-Chlorophenyl)-2-methylthiopyrimidine is used as a potential drug candidate for its antiproliferative and antitumor properties. Its unique structure and properties make it a promising candidate for the development of new drugs in the pharmaceutical industry.
Used in Medicinal Chemistry Research:
4-(4-Chlorophenyl)-2-methylthiopyrimidine is utilized as a subject of research in medicinal chemistry to explore its potential applications and further understand its biological activities. The study of 4-(4-Chlorophenyl)-2-methylthiopyrimidine can contribute to the advancement of drug discovery and the development of novel therapeutic agents.

Upstream product

• 99-91-2 para-chloroacetophenone 
• 28587-05-5 3-dimethylamino-1(4-chloro-phenyl)-2-propen-1-one 
• 17356-08-0 thiourea 
• 74-88-4 methyl iodide 
• 175203-08-4 4-(4-chlorophenyl)-2-pyrimidinethiol 
• 49844-90-8 4-Chloro-2-methylthiopyrimidine 
• 1679-18-1 4-Chlorophenylboronic acid 

Downstream Products

• 1609659-16-6 C₁₇H₁₄ClN₃O 
• 637352-80-8 ethyl [4-({butyl[4-(4-chlorophenyl)pyrimidin-2-yl]amino}methyl)-2-methylphenoxy]acetate 

Relevant academic research and scientific papers

Design, synthesis, and preliminary bioactivity evaluation of N-benzylpyrimidin-2-amine derivatives as novel histone deacetylase inhibitor

Histone deacetylase (HDAC) inhibitors have been identified for the treatment of cancer. Lately, we designed and synthesized a series of substituted N-benzylpyrimidin-2-amine derivatives as potent HDAC inhibitors. In vitro HDAC inhibitory activities and an

NOVEL AMINOMETHYL-PHENOL DERIVATIVES AS ANTIMALARIAL AGENTS

The invention relates to novel aminomethyl-phenol derivatives of formula I wherein R1 to R4, X, A and B are as defined for formula I and their use as active ingredients in the preparation of pharmaceutical compositions. The invention

CHEMICAL COMPOUNDS

A compound of formula (I) or a pharmaceutically acceptable salt, solvate, or hydrolysable ester thereof, .Wherein:R1 and R2 are independently hydrogen or C1-3 alkyl;X represents a bond, CH2 or O;R3 and R4 are independently hydrogen, C1-6 alkyl, OCH3, CF3, allyl or halogen;X1 is CH2, SO2, or CO;R5 is -C1-6 alkyl (optionally substituted by C1-6alkoxy or C1-6alkylthio), -C2-6 alkenyl, -C0-6 alkyl phenyl (wherein the phenyl is optionally substituted by one or more CF3, halogen, C1-3 alkyl, C1-3 alkoxy), -COC1-6 alkyl, SO2C1-6 alkyl ;R6 is phenyl or a 6 membered heteroaryl group containing 1,2 or 3 N atoms wherein the phenyl or heteroaryl group is optionally substituted with 1, 2 or 3 moieties selected from the group consisting of C1-6 alkyl, halogen, -OC1-6 alkyl, -SO2C1-3 alkyl, phenyl (optionally substituted by one or more groups selected from halogen, CF3, C1-3 alkyl, OC1-3 alkyl, acetyl, CN).

Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto

Compounds having activity as inhibitors of IKK are disclosed, particularly IKK-2. The compounds of this invention are anilinopyrimidine derivatives having the following structure: wherein R1 and R6 are as defined herein. Such compounds have utility in the treatment of a wide range of conditions that are responsive to IKK inhibition. Thus, methods of treating such conditions are also disclosed, as are pharmaceutical compositions containing one or more compounds of the above compounds.